ReviewMolecular and cellular pediatrics2018
Precision medicine in pediatric oncology.
Review in Molecular and cellular pediatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Integrative Multiomics and Drug Sensitivity Profiling Reveal Potential Biomarkers and Therapeutic Strategies in Pediatric Solid Tumors.Cancer research · 2026Article
- Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology.NPJ precision oncology · 2026Article
- Determination of a New Biomarker at the Level of Gene Alteration in Cisplatin Ototoxicity.International journal of molecular sciences · 2025Article
- The economic costs of precision medicine for clinical translational research among children with high-risk cancer.NPJ precision oncology · 2024Article
- Article
- Family Recall of and Response to Germline Pathologic Variants Found on Paired Tumor-Germline Sequencing in Pediatric Oncology.JCO precision oncology · 2024Article
- The Health Care Utilization and Medical Costs in Long-Term Follow-Up of Children Diagnosed With Leukemia, Solid Tumor, or Brain Tumor: Population-Based Study Using the National Health Insurance Claims Data.JMIR public health and surveillance · 2023Article
- Article
- Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER'.European journal of cancer (Oxford, England : 1990) · 2022Article
- Review
- Correction to: Precision medicine in pediatric oncology.Molecular and cellular pediatrics · 2022Article
- Metachronous, non-pineal, trilateral retinoblastoma in a patient with a seemingly reduced-expressivityClinical case reports · 2022Article
- Review
- An institutional audit of the use of novel drugs in pediatric oncology.Cancer reports (Hoboken, N.J.) · 2021Article
- The Landscape of Pediatric Precision Oncology: Program Design, Actionable Alterations, and Clinical Trial Development.Cancers · 2021Review
- What Animal Cancers teach us about Human Biology.Theranostics · 2021Review
- Sarcoma treatment in the era of molecular medicine.EMBO molecular medicine · 2020Review
- Review
- The genomic landscape of pediatric cancers: Implications for diagnosis and treatment.Science (New York, N.Y.) · 2019Review
- Prognostic profiling of the immune cell microenvironment in Ewing´s Sarcoma Family of Tumors.OncoimmunologyArticle
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Outcome in treatment of childhood cancers has improved dramatically since the 1970s. This success was largely achieved by the implementation of cooperative clinical research trial groups that standardized and developed treatment of childhood cancer. Nevertheless, outcome in certain types of malignancies is still unfavorable. Intensification of conventional chemotherapy and radiotherapy improved outcome only marginally at the cost of acute and long-term side effects. Hence, it is necessary to develop targeted therapy strategies.Here, we review the developments and perspectives in precision medicine in pediatric oncology with a special focus on targeted drug therapies like kinase inhibitors and inducers of apoptosis, the impact of cancer genome sequencing and immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.